Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01929889 · ClinicalTrials.gov registry record · Phase 4
Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
A Phase 4 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT01929889 is a Phase 4 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 19 participants.
The verdict
NCT01929889, a Phase 4 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The study looks at whether treatment with iloperidone (Fanapt) is associated with improvements in social cognition in individuals who have been recently diagnosed with schizophrenia or schizoaffective disorder. Social cognition (the ability to understand your feelings and the feelings of others) is closely related to functional outcomes, including communication, empathy, and emotional recognition.
Interventions
- DRUG Iloperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01929889
The ClinicalTrials.gov registry entry for NCT01929889 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iloperidone is the first listed.
NCT01929889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01929889 about?
NCT01929889 is a clinical study titled "Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia". The study looks at whether treatment with iloperidone (Fanapt) is associated with improvements in social cognition in individuals who have been recently diagnosed with schizophrenia or schizoaffective disorder. Social cognition (the ability to understand your feelings and the feelings of others) is ...
What is the current status of trial NCT01929889?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2012-04. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01929889?
The interventions under investigation include: Iloperidone (DRUG).
Who is sponsoring clinical trial NCT01929889?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.